Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06508775 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Study acronym: LONGSAFE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints: details revised at 2 of 8 entries Eligibility criteria expanded, about 3 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 3 words
  2. Study sites: 4 to 7v4
  3. Re-verified, no change to tracked fieldsv3
  4. Study sites: 2 to 4v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Miltenyi Biomedicine GmbH
15 trials monitored
See 3 trials at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
Melanoma
1,026 trials monitored
See 48 trials at risk
and 2 more diseases
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
Trial Details
NCT Number NCT06508775
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma, Acute Lymphatic Leukemia, Chronic Lymphatic Leukemia, Melanoma Stage IV
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov